What's more, part of that Prep4pass CCDS-O dumps now are free: https://drive.google.com/open?id=1lYYNnO3zpnnzTk30N3Vi15P_4h1Ct7PK
Do you want to pass CCDS-O exam easily? CCDS-O exam training materials of Prep4pass is a good choice, which covers all the content and answers about CCDS-O exam dumps you need to know. Then you can master the difficult points in a limited time, pass the CCDS-O Exam in one time, improve your professional value and stand more closely to success.
| Topic | Details |
|---|---|
| Topic 1 |
|
| Topic 2 |
|
| Topic 3 |
|
| Topic 4 |
|
>> CCDS-O Reliable Exam Cram <<
The Certified Clinical Documentation Specialist-Outpatient (CCDS-O) product can be easily accessed just after purchasing it from Prep4pass. You can receive free ACDIS Dumps updates for up to 1 year after buying material. The 24/7 support system is also available for you, which helps you every time you get stuck somewhere. Many students have studied from the Prep4pass ACDIS CCDS-O practice material and rated it positively because they have passed the Certified Clinical Documentation Specialist-Outpatient (CCDS-O) certification exam on the first try.
NEW QUESTION # 94
Symbicort is used to treat which of the following conditions?
Answer: C
Explanation:
Symbicort is an inhaled combination medication containing an inhaled corticosteroid (ICS) and a long-acting beta-agonist (LABA). In outpatient chart review, this medication class is most strongly associated with chronic airway inflammatory diseases requiring controller therapy-especially persistent asthma (and also maintenance therapy for COPD, though COPD is not an option here). For CDI purposes, medication-to-diagnosis linkage can act as a clinical indicator supporting clarification when the visit note lists respiratory symptoms but does not clearly document the chronic condition being treated or its acuity/status. Symbicort is not used to treat musculoskeletal degenerative disease (osteoarthritis), peripheral nerve pain from diabetes (diabetic neuropathy), or cardiac pump failure (congestive heart failure). When Symbicort appears on the active med list, outpatient CDI commonly checks that the provider's documentation appropriately reflects asthma classification (intermittent vs persistent), current control, exacerbation status if applicable, and that the condition is being monitored/assessed/treated during the encounter to support reportability and accurate coding.
NEW QUESTION # 95
Which of the following lab values, when trended for greater than 3 months, indicates an objective measure of chronic kidney damage?
Answer: A
Explanation:
Chronic kidney disease (CKD) is defined by evidence of kidney damage or reduced kidney function that persists for at least three months. An estimated glomerular filtration rate (eGFR/GFR) below 60 mL/min sustained over that timeframe is an objective indicator of chronically decreased renal function and supports CKD identification and staging in the outpatient record. This is why outpatient CDI programs frequently use trended eGFR as a clinical indicator to prompt documentation of CKD stage (e.g., stage 3a/3b, stage 4, etc.) when appropriate. BNP >1000 is more aligned with heart failure severity/volume status rather than kidney damage. BUN <12 is within/near normal and does not indicate renal impairment (elevated BUN may be seen with renal dysfunction but is less specific and affected by hydration, diet, GI bleed). Glucose >100 is a screening indicator for impaired fasting glucose/prediabetes but does not, by itself, establish chronic kidney damage. Therefore, sustained GFR <60 is the best objective lab-based measure of chronic kidney damage over time.
NEW QUESTION # 96
Which of the following BEST defines a risk score under the CMS-HCC model?
Answer: B
Explanation:
Under the CMS-HCC model, a beneficiary's risk score (RAF) is intended to represent the expected cost of caring for that individual relative to an average beneficiary. The score is calculated using two primary inputs: (1) the beneficiary's demographic factors (such as age, sex, Medicaid status/dual eligibility, disability status, and original reason for Medicare entitlement, depending on the model segment), and (2) the beneficiary's documented disease burden captured through ICD-10-CM codes that map to Hierarchical Condition Categories (HCCs). Those HCCs reflect the person's health status and severity, with hierarchy rules preventing "stacking" of related conditions and with certain interaction terms in some model versions. Social determinants are not generally described as the defining basis of the traditional CMS-HCC RAF in CDI education, and "family demographics" are not used. The model is not a mortality predictor; it is a cost/risk prediction tool for payment adjustment. Therefore, the best definition is the beneficiary's individual demographic and health status.
NEW QUESTION # 97
Which of the following therapies is MOST likely to be recommended?
Answer: C
Explanation:
Metoprolol is a beta-blocker commonly used in atrial fibrillation to achieve ventricular rate control, reduce symptoms (palpitations, dyspnea), and improve hemodynamic stability, especially when the rhythm is persistent or recurrent. From an outpatient CDI chart-review perspective, therapy-to-diagnosis consistency is a key clinical indicator that supports clarifying the condition being treated and ensuring it is documented as assessed/managed at the encounter. The other options are clinically mismatched: "Ensure" is a nutritional supplement typically used for inadequate intake or weight loss and would not be recommended for morbid obesity; rivaroxaban (Xarelto) is an anticoagulant and would be inappropriate in the setting of hematemesis (active GI bleeding) where anticoagulation generally increases risk and would typically be held or reassessed; tamoxifen is an endocrine therapy for hormone receptor-positive breast cancer risk/treatment and is not a standard therapy for chronic congestive heart failure. Therefore, metoprolol for atrial fibrillation is the most appropriate and likely recommendation among the choices.
NEW QUESTION # 98
When a CDI specialist identifies a discrepancy in documentation, the next step is to:
Answer: A
Explanation:
CDI staff do not alter the legal health record and should not "code it as is" when documentation is unclear, conflicting, or incomplete in a way that impacts accurate reporting. The compliant next step is to issue a provider query for clarification, ensuring the final record accurately reflects the provider's clinical judgment. ACDIS-guided outpatient CDI emphasizes that queries are a quality and compliance tool: they reconcile discrepancies (e.g., conflicting diagnoses across notes, missing linkage between symptoms and conditions, unclear acuity such as "CHF" without type/status, or ambiguous infection documentation). The query should be supported by clinical indicators from the chart and should ask the provider to document the clarified diagnosis/status in the record (progress note, addendum, or appropriate attestation). Escalation to compliance is reserved for patterns of nonresponse, suspected integrity concerns, or systemic issues, not routine discrepancies. The objective is to achieve a complete, consistent clinical story that supports coding, risk adjustment, quality reporting, and medical necessity-through provider clarification, not CDI edits.
NEW QUESTION # 99
......
For candidates who want to start learning immediately, choosing us will be your best choice. Because you can get the downloading link within ten minutes after purchasing, so that you can begin your study right now. What’s more, CCDS-O training materials of us are also high-quality, and they will help you pass the exam just one time. We are pass guaranteed and money back guaranteed for your failure. We also have a professional service stuff to answer any your questions about CCDS-O Exam Dumps.
Valid CCDS-O Exam Camp Pdf: https://www.prep4pass.com/CCDS-O_exam-braindumps.html
P.S. Free & New CCDS-O dumps are available on Google Drive shared by Prep4pass: https://drive.google.com/open?id=1lYYNnO3zpnnzTk30N3Vi15P_4h1Ct7PK